




Fig. 1.




Fig. 2.




Fig. 3.




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8





Fig. 9



Tiempo(h)

Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17

a. Los pacientes del Grupo 2 recibirán dos inyecciones subcutáneas de placebo (1.0 mL cada una) en el Día 1 de las semanas 4 y 8





Fig. 18



Фиг.19




Fig. 20




Fig. 21




Fig. 22

Fig. 22





Fig. 23








Fig. 25




Fig. 26




Fig. 27




Fig. 28




Fig. 29




Fig. 30




Fig. 31




Fig. 32




Fig. 33